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AbstrAct:
Inhibitors of angiogenesis are an important addition to conventional chemotherapy. 
Among different “druggable” angiogenic factors, fibroblast growth factor-2 (FGF-
2) is an attractive target for novel therapies because of its intricated involvement 
in tumor neovascularization, tumor cell proliferation and migration, and the 
acquisition  of  resistance  to  antiangiogenic  therapies.  FGF-2  bioavailability  and 
activity is affected by several natural ligands, including the endogenous inhibitor of 
angiogenesis thrombospondin-1 (TSP-1). We hypothesized that the FGF-2-binding 
sequence of TSP-1 might serve as a template for the development of non-peptide 
inhibitors of angiogenesis. Computational biology and nuclear magnetic resonance 
spectroscopy approaches, major investigative tools in the characterizations 
of protein-protein interaction (PPI), were used to map the residues at the TSP-
1/FGF-2  interface.  The  translation  of  this  three-dimensional  information  into 
a pharmacophore model allowed screening a small molecule databases, 
identifying three FGF-2-binding, antiangiogenic small molecules, mimetic of TSP-
1. Pharmacophore-based approaches are thus feasible tools to exploit naturally 
occurring PPI, by generating a set of lead compounds mimetic of endogenous 
proteins, as a starting point for the development of novel therapeutic agents.
IntroductIon
Angiogenesis has become a successful target in 
cancer therapy [1]. Designed to target the formation of 
a functional vascular network – a requirement for the 
malignant progression -, antiangiogenic agents impair 
tumor growth and metastatic dissemination [2]. These 
drugs, mostly inhibitors of the angiogenic factor vascular 
endothelial growth factor (VEGF), have become important 
tools in the clinical practice, usually in combination with 
conventional chemotherapy. However, antiangiogenic 
therapies still cause only a modest increment of overall 
survival, and often present relevant toxic effects. The lack 
of long-lasting therapeutic effects of the antiangiogenic 
therapies in neoplastic patients is due to acquired 
(“evasive”) resistance to these agents resulting from a 
concurrence of causes including tumor adaptation to 
growth in an angiogenesis-independent manner, selection 
of more malignant and invasive tumor cells by therapy-
induced hypoxia, and increased production of angiogenic 
factors, equal and/or different from the targeted one [3]. 
Several approaches have been proposed to overcome 
resistance. The optimization of schedule of administration 
and length of treatment with the antiangiogenic agents is 
certainly a relevant issue. In addition, the simultaneous 
targeting of different angiogenesis pathways is another 
possible approach to overcome the arising of resistance. 
So far, the antiangiogenic agents approved for clinical 
use target (exclusively or preferentially) VEGF. The 
design of agents targeting other angiogenic factors is Oncotarget 2010; 1:  662 - 673 663 www.impactjournals.com/oncotarget
becoming a promising field for the development of novel 
antiangiogenic compounds, further supported by the 
evidence of selective, non-redundant roles of the different 
angiogenic factors produced by tumors in promoting not 
only tumor angiogenesis and metastasis, but also the 
direct growth and invasion of tumor cells [4]. Therefore 
each angiogenic factor represents an important target for 
therapy of tumors, challenged or not with antiangiogenic 
therapies. 
AngIogenIc growth fActors As 
tArgets: the prototype fgf-2
Numerous inducers of angiogenesis have been 
identified,  including  the  members  of  the  already 
mentioned VEGF family, hepatocyte growth factor 
(HGF), angiopoietins, transforming growth factor-α 
and -β (TGF-α and -β), platelet-derived growth factor 
(PDGF), tumor necrosis factor-α (TNF-α), interleukins, 
chemokines, and the members of the fibroblast growth 
factor (FGF) family [1, 2, 5].
Beside VEGFs, FGFs are recognized targets for the 
development of anti-cancer therapy [6, 7]. FGF-2 has 
been the first tumor-associated angiogenic factor to be 
purified [8]. Since then, an increasing amount of evidence 
has accumulated supporting the involvement of FGFs 
in different steps of cancer progression. Overexpression 
or genetic alterations lead to a deregulated activation of 
FGF/FGF receptor pathways in cancer [7]. Plasma levels 
of FGFs are frequently elevated in cancer patients, in some 
cases associated with tumor escape from antiangiogenic 
therapy [9]. Evidences indicate that FGFs, produced by 
both tumor or host cells, promote tumor progression 
both directly, by affecting tumor cell differentiation, 
proliferation, survival, invasion, metastasis, response 
to chemotherapy and cancer stem cell self-renewal, 
and indirectly, by inducing angiogenesis as well as the 
recruitment and activation of tumor-supporting stromal 
cells [6, 7]. Therefore targeting FGFs has a multivalent 
value as a way to simultaneously affect different pathways 
associated with both tumor progression, angiogenesis, 
host cells recruitment and tumor resistance. 
At present, 22 structurally-related members of the 
FGF  family  have  been  identified,  including  18  FGFs 
(defined as FGF receptor ligands) and 4 FGF-homologous 
factors [6, 7, 10]. FGFs are pleiotropic factors that act on 
different cell types in autocrine, paracrine of juxtacrine 
manners, through different receptors, including tyrosine 
kinase (TK) receptors (FGFRs), heparan-sulfate 
proteoglycans (HSPGs), integrins, and gangliosides. 
Among the paracrine FGFs, FGF-1, 2, 4, 5 and 8 have 
pro-angiogenic activity [11].
The angiogenic activity of FGFs can be neutralized 
by different strategies, schematized in Figure 1. For a 
detailed review see [6, 7, 12].
Inhibition of FGFs production/release by FGFs 
producing cells (leukocytes, tumor, and stromal cells) can 
been achieved by antisense or dominant negative cDNAs 
approaches. Interestingly, chemotherapeutics have been 
demonstrated to inhibit FGF production, mainly by 
affecting FGF-producing tumor cells.
Once produced and released, FGFs can be sequestered 
in the extracellular space preventing their paracrine or 
autocrine stimulation of target cells. This can be achieved 
with anti-FGFs antibodies or with FGF traps, designed 
to mimic FGF-sequestering molecules. The finding that 
the released, soluble extracellular portion of the FGFR1 
binds FGF-2 and prevents FGF-2/FGFR1 interaction has 
led to the design of FP-1039, a soluble fusion protein that 
consists of extracellular FGFR1-IIIc domain fused to the 
Fc domain of IgG1.
Heparin, a negatively charged glycosaminoglycan 
released  in  the  blood  stream  during  inflammation, 
sequesters FGFs in the extracellular environment, 
efficiently competing for the binding of the growth factor to 
HSPGs. Although it exerts a potent FGF-antagonist effect, 
unmodified heparin cannot be used as an anti-angiogenic 
drug because of its anticoagulant activity and binding to 
a wide array of physiological molecules. This prompted 
the development of synthetic heparin derivatives and 
heparin-like molecules (such as the prototypic suramin) 
endowed  with  a  more  specific  FGF-antagonist  activity 
and a more favorable therapeutic window (reviewed 
in [12, 13]). Among structurally different derivatives, 
Gentisic acid (2,5-dihydroxybenzoic acid), a widespread 
plant secondary metabolite and a catabolite of aspirin, 
binds the heparin-binding site of FGF and has been used 
as a template to develop inhibitors of angiogenesis [14].
FGF receptors and ligands (including FGFRs, 
HSPGs, integrins and gangliosides) are important targets 
to block FGFs activity. The binding of FGFs to their 
FGFRs can be neutralized by specific antibodies directed 
against the receptors or by protamine or synthetic peptides 
corresponding to the receptor recognition sequences of 
FGFs. HSPGs can be masked by protamine, histidine-rich 
glycoprotein, PF4, endostatin and kallistatin. Integrins-
FGF interactions are masked by synthetic peptides, 
peptidomimetics and disintegrins (a class of naturally 
occurring integrin antagonists) containing integrin-
recognition motifs such as RGD. Finally, the cholera 
toxin B subunit binds to cell surface GM1 ganglioside 
hampering its interaction with FGF-2 thus inhibiting FGF-
2-dependent pro-angiogenic activation of endothelial 
cells.
The blockage of FGF activity can be achieved by 
hampering the expression of the various FGF receptors 
on target cells, including FGFRs, HSPGs, integrins, 
and gangliosides. FGFRs expression can be reduced 
by antisense cDNA, the synthetic retinoid fenretinide, 
and antibodies directed against αvβ3 and α5β1 integrins. 
Perlecan antisense cDNA and lead exposure cause HSPG 
downregulation. Finally, inhibitors of the synthesis of Oncotarget 2010; 1:  662 - 673 664 www.impactjournals.com/oncotarget
complex gangliosides, including fumonisin B1, D-threo-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol, and 
D-1-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-
1-propanol, inhibit EC proliferation triggered by FGF-2.
The TK activity of angiogenic factor receptors is a 
successful strategy to affect angiogenesis, as shown by 
the number of TK inhibitors that have been subjected 
to clinical trials or approved in the last decade. Most 
TK inhibitors have a broad-spectrum activity, affecting 
multiple receptors and pathways, as in the case of 
SU5402, that targets both VEGFR-2 and FGFR1. Efforts 
are currently ongoing to design TK inhibitors selective for 
the FGFRs, such as PD173074, selective for FGFR1 and 
FGFR3 [6, 7]. Recently, structure-guided approaches are 
being used to introduce focused structural changes and 
optimize potency and selectivity of TK inhibitors [15].
Intracellular signals activated by FGFs in tumor 
cells or ECs might be considered targets for angiogenesis 
inhibitors. A long list of synthetic compounds, dominant 
negative mutants or antisense cDNAs targeting FGFs-
dependent signalling pathways has been described. 
Finally, the “pro-angiogenic phenotype” induced by FGF-
2 in endothelial cells, can be targeted by agents preventing 
FGF-induced invasion, motility, matrix degradation, 
proliferation and survival.
endogenous InhIbItors 
As templAtes to desIgn 
AntIAngIogenIc Agents: tsp-1
Endogenous inhibitors of angiogenesis have evolved 
as the optimal physiological control of the angiogenic 
process. It is therefore logical to consider them as models 
for the design of antiangiogenic therapies [16]. This 
heterogeneous group of molecules includes proteins, 
polysaccharides and glycosphingolipids found in the body 
fluids and ECM. 
Thrombospondin-1 (TSP-1) was the first endogenous 
inhibitor of angiogenesis to be identified [17, 18]. Of the 
5 members that compose the TSP family in mammals, 
TSP-1 and TSP-2 (forming the group A, homotrimeric 
TSPs) are similar in domain organization and share the 
ability to inhibit angiogenesis. TSPs are modular proteins. 
Each TSP-1 monomer consists of an N-terminal globular 
figure 1: strategies for inhibiting fgfs. Inhibitors of FGFs can act by reducing FGF production by the tumor (1), interfering with FGF-
FGFR recognition (2,3), affecting endothelial cells expression of FGFR (4), inhibiting FGF-induced intracellular signalling pathways (5), or 
act downstream FGFs, on effectors of angiogenesis (6).
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domain, followed by the coiled-coil oligomerization 
domain, a von Willebrand Factor type C, procollagen 
domain, three properdin-like type I repeats, and a 
signature domain comprising three epidermal growth 
factor (EGF)-like type II repeats, a calcium-binding wire 
- type III repeats, and the lectin-like C-terminal globular 
domain [19]. 
TSP-1 is a matricellular protein, i.e. a non-structural 
extracellular protein that acts to regulate cell interactions 
with the environment [20]. Through its different domains, 
TSP-1 is able to interact simultaneously with different 
cell receptors, soluble cytokines and growth factors, 
extracellular matrix components, and proteases. This 
accounts for the pleiotropic nature of TSP-1, which, 
depending on the environmental properties (presence of 
receptors, ligands, proteases) can have different effects - 
even opposite - on cell activities and biological process 
[21-23]. Such a large, modular protein has the potential to 
aggregate molecular complexes at the pericellular level, 
acting as a scaffold that place in close proximity soluble 
molecules, growth factors, proteases and recruited cell 
receptors, ultimately orchestrating a complex signaling 
cascade within the cells (Figure 2). On the other hand, 
proteolytic digestion of TSP-1 generates active fragments 
which are still able to interact with their ligands, without 
however generating large molecular complexes, and 
hence with functional consequences different from 
entire TSP (Figure 2). The generation of antiangiogenic 
fragment of TSP-1 by proteases has been described [24], 
and indeed, proteolytic degradation of large molecules 
is emerging as an important mechanism to generate 
inhibitors of angiogenesis [25]. In the case of TSPs, it 
can be anticipated that antiangiogenic fragments might 
be characterized and taken as models for the design of 
inhibitors of angiogenesis.
TSP-1 can inhibit angiogenesis both directly and 
indirectly [26]. As a direct inhibitor it interacts with 
specific receptors on endothelial cells (including CD36, 
CD47, integrins, HSPG, and LRP) to affect cell viability 
and functions related to angiogenesis. Besides endothelial 
cells, TSP-1 is also active on other cell types involved in 
the angiogenic process, including smooth muscle cells, 
monocytes/macrophages and T cells. Finally, TSP-1 
has been reported to decrease the mobilization of viable 
circulating endothelial cells and putative endothelial 
progenitor cells [27].
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As an indirect inhibitor, TSP-1 binds and modulates 
the activity/bioavailability  of different mediators of 
angiogenesis, such as angiogenic factors, cytokines and 
proteases. The interaction of TSP-1 with the angiogenic 
factors FGF-2, VEGF, HGF, PDGF and the viral protein 
Tat [28-32], might be viewed as a general mechanism of 
angiogenesis regulation and thus a paradigm for designing 
therapeutic intervention.
Different therapeutic approaches have been 
proposed to exploit the antiangiogenic properties of TSP-
1 (reviewed in [33-35]). Increased levels of TSP-1 have 
been obtained by gene therapy approaches, based on 
viral and non-viral vectors, designed to grant the constant 
delivery of the antiangiogenic factors necessary for an 
effective control of angiogenesis [36, 37]. Alternatively, 
different classes of antiangiogenic compounds stimulate 
TSP-1 production, including fenofibrate, thrichostatin-A, 
retinoic acid, inhibitors of DNA methyltransferases and 
histone deacetylases (see [33, 34] and references therein). 
Interestingly, an increase in TSP-1 production has been 
indicated as the main mechanism of the antiangiogenic 
activity of metronomic chemotherapy, the frequent 
administration of low dose chemotherapy proposed to 
optimize the antiangiogenic property of chemotherapeutics 
[38, 39].
Different antiangiogenic sequences have been 
identified  in  TSP-1,  each  offering  a  potential  tool  for 
therapeutic exploitation [34, 35]. Synthetic peptides based 
on the active sequences of TSP-1 have antiangiogenic 
and antineoplastic activity. Chemical modifications - such 
as use of non-natural amino-acids, cyclization, linkage 
to proteins, retro-inverso analogues, or polysucrose 
conjugates - can be successfully used to increase peptide 
stability, bioavailability, potency, tumor targeting ability, 
and to improve pharmacokinetics/pharmacodinamics 
(PK/PD) [23, 40-42]. Two TSP-1-based peptido-mimetics 
developed as antiangiogenic agents for antineoplastic 
therapy, have reached clinical trials, ABT510 and 
CVX-045. ABT-510 is a modified peptide, based on the 
7-mer active sequence GVITRIR present in the second 
type I repeat of TSP-1 [41]. It induced endothelial cell 
apoptosis in vitro and inhibited angiogenesis in in vivo 
assays [43]. ABT-510 and the related peptide ABT-526 
inhibited tumor growth and reduced microvessel density 
in preclinical tumor models [43-45], and were particularly 
active in combination with chemotherapy [46, 47] or 
other antiangiogenic agents [48]. CVX-045 is a fusion 
molecule, produced by covalently attaching two TSP-1 
mimetic nonamer peptides to the Fab binding site of a 
humanized scaffold antibody, which endows the molecule 
with the advantageous PK of antibodies. CVX-045 has 
been reported active in xenograft tumor models, both as 
single treatment and in combination regimens [49].
exploItIng proteIn-proteIn 
InterActIons In drug dIscovery
The TSP-1/FGF-2 interaction and its exploitation 
in the design of inhibitor peptide sequences represents a 
paradigmatic example of how the knowledge of naturally 
occurring protein-protein interactions can be exploited in 
the discovery of new drug-like inhibitors. 
Indeed, protein-protein interactions (PPIs) play 
fundamental roles in all biological processes, and underlie 
a wide variety of complex pathways fundamental for 
either the correct functioning of cells or the development 
of pathological conditions [50]. As a consequence, it is 
not surprising that over the last few years the study and 
targeting of protein-protein interactions has attracted ever 
growing attention [51]. 
The development and success of structural 
and functional genomics initiatives combined to the 
improvements in proteomics and bioinformatics have 
provided a wealth of structural and functional information 
on PPI’s [52-54]. This information can now be used to 
discover small molecules that mimic the functions of one 
of the two binding partners, thus acting as antagonists or 
regulators in pathways where a certain PPI is particularly 
relevant. 
However, targeting protein-protein interaction 
interfaces has proven to be a challenging task in drug 
discovery [55]. The contact surfaces may indeed be large 
and  rather  flat,  compared  to  the  well-defined  cavities 
that are typically exploited in targeting enzyme active 
sites in classical drug discovery efforts. Moreover, in 
many cases, most of the contacts defining the surfaces 
involve aminoacids that are not contiguous in the primary 
sequence. Consequently, peptides derived from short 
sequences may represent poor starting points from the 
medicinal chemistry point of view. In the same frame of 
thought, in most cases, there is no natural small molecule 
partner that either mediates or takes part in protein-
protein interactions. Thus, in contrast to the development 
of enzyme inhibitors, there is no small molecule substrate 
or ligand to use as a starting point for modifications or 
mimics-development. 
Despite all these hurdles, several success stories 
have emerged that provide confidence in the quest for 
small molecule inhibitors of PPI’s. 
Great impulse to this has come from the availability 
of a number of high resolution X-ray structures of protein-
protein complexes and from the study of the effects of 
complex formation on the conformational properties 
of the partners from NMR experiments [56, 57]. The 
combination of this structural information with the results 
of mutational studies has helped identify small-subsets of 
residues contributing most of the free energy of complex 
stabilization. The chemical properties and positioning of 
these “hot spots” can then be exploited as templates for 
the design of new small-molecules, as targets for fragment Oncotarget 2010; 1:  662 - 673 667 www.impactjournals.com/oncotarget
based drug development or for focusing high throughput 
screening campaigns. 
The analysis of the properties of protein-protein 
complexes, combined to mutational scanning has 
led to the development of inhibitors of the cytokine 
Interleukin-2  [58]  binding  to  its  receptor.  Another 
example is represented by the members of the B-cell 
lymphoma 2 (Bcl-2) family. These proteins, indicated as 
Bcl-XL are important regulators of apoptosis. They form 
homodimers or heterodimers with other members of the 
family generating antiapoptotic complexes, important 
in tumor development and progression [59]. Analyzing 
the binding of these proteins to specific helical regions 
of BAK of BAD, it was possible to develop and design 
small molecules able to selectively disrupt the target 
protein-protein interactions with important anticancer 
activities [60]. Similar approaches have been applied to 
identify new inhibitors of the p53-HDM2 interactions or 
disruptors of TNF dimers [61]. 
An important development for the discovery of 
new PPI inhibitors may stem from the realization that 
interacting surfaces are not static. Rather, they are highly 
dynamic. Computational methods, mainly based on 
all-atom Molecular Dynamics simulations, now offer 
unprecedented possibilities to design molecules and 
pharmacophore  models  that  target  flexible  receptors, 
taking multiple different conformational states available 
on the protein’s energy landscape. Including an atomic 
level resolution description of the adaptation of the two 
binding partners to each other and/or differences in the 
solution behavior compared to the X-ray situation in 
the small molecule selection process has the potential to 
extend the chemical space of PPI inhibitors suggesting 
new structures, chemotypes and ultimately drugs [62-64].
Computational studies have to be validated 
experimentally to be really helpful in the context of 
rational drug design. NMR has recently emerged as 
a high-throughput experimental technique in drug 
discovery, in determining possible binding affinities and 
in characterizing the regions of interaction. NMR analysis 
helps selecting and filtering only those conformations that 
verify specific structural constraints obtained in solution 
at equilibrium, recapitulating ensemble properties that 
are specific only to selected molecular configurations. In 
particular the recent development of new exchange-based 
methods makes NMR spectroscopy a unique tool for 
accessing huge and heterogeneous systems reducing or 
eliminating the molecular weight limitations for receptors 
in interaction studies. These methods, giving exchange-
transferred structural information at high sensitivity on 
receptor-bound ligands from unbound-state resonances, 
are very useful to study the interactions of small molecules 
or proteins with very large systems, with no need of 
labeling [65-67].
Overall, these concepts provide a solid basis to 
integrate structural, dynamic, biochemical and molecular 
biology information explicitly in the drug discovery 
process. In this context, the molecular information on 
figure 3: schematic representation of the approach undertaken to develop non peptidic, small molecule inhibitors of 
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TSP-1/FGF-2 binding has been exploited to discover new 
inhibitors of angiogenesis. 
exploItAtIon of the fgf-2-bIndIng 
sequence of tsp-1 for the desIgn 
of AntIAngIogenIc compounds
As mentioned above, a common aspect of a number 
of endogenous inhibitors of angiogenesis, including TSP-
1, is the ability to bind and sequester angiogenic factors. 
Our work hypothesis was therefore to characterize and 
exploit this property of TSP-1 to design inhibitors of 
angiogenesis (Figure 3). 
TSP-1  binds  FGF-2,  with  high  affinity  (in  the 
nanomolar range), similar to the affinity of the growth 
factor for heparin [29, 31]. Consequently to this 
interaction, TSP-1 prevents FGF-2 binding to HSPG in the 
extracellular matrix and on the surface of endothelial cells 
[30], inhibiting FGF-2-mediated pro-angiogenic activation 
of endothelial cells, and depleting the extracellular matrix 
of stored FGF-2, an important component in the process 
of neovascularization [29, 30]. 
In order to exploit the FGF-2-binding region of 
TSP-1,  we  first  needed  to  identify  the  FGF-2-binding 
sequence. We therefore designed an approach allowing 
the  identification  of  progressively  smaller  FGF-2-
biding site in TSP-1. Thrombin-generated, proteolytic 
fragments  of  TSP-1  were  first  used,  and  showed  that 
the FGF-2-binding ability was retained by the 140 kDa 
carboxy-terminal domain [29, 30]. Using recombinant 
portions of TSP-1, we identified a previously undescribed 
antiangiogenic site in the type III repeats of TSP-1, and 
demonstrated that binding of the angiogenic factor FGF-2 
to this site inhibits angiogenesis by sequestration of FGF-
2 [31]. Finally, the peptide array technology allowed us to 
identify three potentially active linear sequences involved 
in the interaction of FGF-2 with the type III repeats of 
TSP-1 [68]. Binding experiments and SPR analysis with 
synthetic peptides corresponding to these sequences 
indicated that one of them, DDDDDNDKIPDDRDN 
(residues 739-753; named DD15) indeed bound FGF-
2  with  a  Kd  of  28.0  µM. In agreement with previous 
findings showing that TSP-1 impaired FGF-2 interaction 
with heparin, molecular dynamics (MD) analysis of the 
figure 4: chemical structures of sodium 5-amino-2-naphthelenesulfonate (c9, [69]) and of the active (sm8 and sm27) and 
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DD15/FGF-2 complex indicated that the peptide adopted 
an extended conformation over FGF-2 binding surface, 
occupying the heparin-binding site, with favorable 
electrostatic couplings between the Lys sidechains on the 
surface of FGF-2 and the negatively charged Asp groups 
of DD15.
Once  a  bioactive  protein  sequence  is  identified, 
two main approaches can be undertaken to develop 
active mimicking compounds: i) the design of natural or 
modified synthetic peptides or ii) the development of non-
peptidic mimetic small molecules. In our case, the former 
option was hindered by the poor affinity of the peptide 
for FGF-2, and by the general poor pharmacological 
properties of peptides. We thus decided to undertake a 
search for non-peptidic, small molecule mimetic of TSP-
1, using a pharmacophore-based approach that allows 
a high-throughput search of molecules presenting the 
correct spatial geometry of the functional groups required 
for target recognition. The power of this approach is the 
possibility of selecting chemically different compounds 
having the same target recognition and biological activity, 
therefore offering broad possibilities of lead selection for 
future pharmacological development.
The information independently obtained by MD 
simulations and experimental NMR data was combined 
to  provide  a  cross-validated  and  cross-filtered  atomic 
resolution model of the complementary interactions 
within the binding site.  The results of extensive all-
atom MD simulations provided a statistically weighted 
description  of  the  most  relevant  interactions  defining 
binding. It is worth noting that this MD-based approach 
was developed to analyze the complex interface while 
taking account of conformational dynamics and motional 
flexibility  of  both  binding  partners  and  focusing  in 
particular on hydrogen-bonding, hydrophobic/aromatic, 
and charge-charge interaction [68]. NMR analysis, based 
on Saturation Transfer Difference (STD) experiments 
[65], identified and confirmed the identity of the peptide 
residues making interaction with FGF-2. Altogether, MD 
and NMR analyses yielded a consistent identification of 
DD15 residues mostly involved in the recognition of FGF-
2 and stabilization of the complex, indicating that both 
hydrophobic and electrostatic contributions are relevant to 
the interaction.
After analyzing the MD trajectories, the groups of 
DD15 mostly involved in stabilizing the complex with 
FGF-2 and their average relative positioning were identified 
and this information translated into a pharmacophore 
model that recapitulated the minimal functional and 
stereochemical requirements needed by a molecule to 
bind FGF-2. In particular, three pharmacophoric points 
were considered: two negative ionizable functionalities 
mapped over the carboxy groups of Asp741 and Asp750, 
and one five- or six-membered ring moiety mapped on the 
position of the corresponding ring of Pro748, to mimic 
the peptide hydrophobic patch defined by Ile747-Pro748 
and provide structural rigidity to hits. The pharmacophore 
was used to screen the NCI2003 database of molecules 
(Developmental Therapeutics Program NCI/NIH).  This 
search yielded 42 molecules. Nineteen of them, made 
available from the NCI (Rockville, MD) were subjected 
to experimental analysis of FGF-2 binding. Three 
molecules (named sm8, sm27, and sm10, Figure 4) were 
indeed able to bind FGF-2 with Kd ranging from 0.4 to 
34  µM). Importantly, the small molecules retained the 
antiangiogenic activity of the entire TSP-1 and the type 
III repeats, as they prevented the binding of FGF-2 to 
endothelial cells and inhibited FGF-2-induced endothelial 
cell proliferation. Moreover, the most active molecule, 
sm27, inhibited FGF-2-induced angiogenesis in the 
chicken chorioallantoic membrane assay[68]. 
Interestingly these molecules met the stereochemical 
rules, obtained through a totally different approach, 
proposed to develop naphthalene sulfonates as FGF 
inhibitors [69]. In an attempt to identify new naphthalene 
derivatives that combine the highest inhibitory activity 
with the lowest toxicity, Fernandez-Tornero and coworkers 
explored a wide window of charge, size and relative 
position of substituents of the naphthalene ring This 
study allowed formulating the following stereochemical 
rules that may constitute the basis for the development of 
new antiangiogenesis treatments: 1) the sulfonate group 
should preferentially be located at position 2 rather than 1 
of the planar aromatic ring of naphthalene; 2) derivatives 
containing one amino group at positions 5 or 6 are better 
inhibitors of aFGF mitogenic activity; 3) the size of the 
functional group at position 5 or 6 seems very relevant, 
because  a  significant  impairment  was  evident  when  a 
bulky amide is introduced
It is interesting to make a comparative analysis 
between the structure/inhibition relationship of the most 
active compound found by Fernandez-Tornero and 
coworkers, the sodium 5-amino-2-naphthelenesulfonic 
acid (C9) and those of the most active (sm8 and sm27) and 
the less active (sm10) leads identified by our group [68] 
(Figure 4). The half-maximum inhibitory activity of sm27 
(IC50 = 20 µM ) is more than one order of magnitude 
lower than that of C9 (265 µM). Indeed, both sulfonate 
groups are located at position 2 and both amino groups 
at position 6, in good agreement with the stereochemical 
rules formulated. The half-maximum inhibitory activity of 
sm8 (IC50 = 67.8 µM) is four times lower than that of C9, 
but three times higher than that of sm27. These features 
might be rationalized considering that, even if the size and 
functional groups are exactly the same, only one sulfonate 
group is located at the right position 2 in sm8 (the other 
one being at the wrong position 3) and only one amino 
group is located at the right position 6, while the other 
one is at the wrong position 7. Finally sm10, which does 
not respect at all the mentioned stereochemical rules, is 
endowed with modest inhibitory effect.
Our approach has allowed the identification of active Oncotarget 2010; 1:  662 - 673 670 www.impactjournals.com/oncotarget
small molecules mimetic of TSP-1. These leads cannot 
yet be considered real drug candidates, and additional 
efforts are required to further derivatize the leads through 
a combination of combinatorial chemistry, molecular 
dynamics and docking approaches guided by NMR 
experimental restraints, to improve on their drug-like 
properties and FGF-2 targeting affinity and specificity. The 
latter issue is particularly important, since the possibility 
exists that small molecules might partially lose the high 
specificity typical of peptides and eventually interact with 
additional targets originally not recognized by the peptide. 
We  believe  that  our  study  has  confirmed  the 
reliability of the pharmacophore-based strategy to develop 
active compounds mimetic of endogenous inhibitors for 
pharmacologic use. Other studies integrating 3D structural 
and the screening of libraries of natural products led to 
the discovery of a new chemical class of FGF inhibitors. 
Combining screening, X-ray structure determination 
and NMR studies to cell biology methods, proliferation 
assays and angiogenesis assays Gimenez-Gallego and 
coworkers [14] were able to identify Gentisic acid 
derivative as possible starting points for the development 
of angiogenesis inhibitors with promising therapeutic 
properties in vivo. 
conclusIons
The identification of TSP-1-mimetic antiangiogenic 
leads support the hypothesis that integrated 
multidisciplinary approaches can be successfully used 
to develop non-peptidic small molecule mimics of 
endogenous proteins as therapeutic agents. These leads 
represent a starting point for the future development of 
antiangiogenic agents.
This study opens new themes of investigations. 
Heparin recognition is a common feature of angiogenic 
factors. It is therefore conceivable that TSP-1, its active 
sequence DD15 and the identified small molecule sm27 
would bind and inhibit the activity of other angiogenic 
factors. Should this be the case, a compound similar 
to sm27 might be envisioned as a general recognition 
backbone for heparin-binding angiogenic factors, 
whereas further chemical modification might be designed 
to tune its selectivity for specific angiogenic factors. In 
this respect, it is worth noting that the structure of sm27 
closely mirror that of Surfen [70]. The positively charged 
groups of Surfen which substitute the negatively groups 
of sm27, confers Surfen with the ability to bind to HSPG 
blocking their interactions with FGF-2. This indicates that 
the common backbone shared by Surfen and sm27 might 
indeed meet the correct spacial requirements to interfere 
with protein/HSPG interaction. 
Another potential area of research is the analysis 
of sequences similar to DD15 present in other proteins, 
including members of the TSP family as well as proteins 
unrelated to TSPs. This might lead to the recognition of 
other proteins or protein fragments able to interact with 
angiogenic factors, and possibly to the identification of 
a class of inhibitors sharing a similar structure/activity. 
Moreover, since FGF-2 is not only an angiogenic factor, 
but also a major promoter of tumor cell malignant behavior, 
the possibility exists that TSP-1, DD15 and sm27 have 
a direct anti-invasive and anti-metastatic activity, that 
warrants further investigation.
Finally, we think it is important to underline that 
our data, together with the results from other groups, 
demonstrate that exploiting the new knowledge on 
PPIs important for the regulation of angiogenesis, the 
integration of different levels of information ranging 
from the functional level to the dynamic determinants of 
specific molecular recognition events may ultimately spur 
the discovery of new drug classes active on challenging 
targets,  overcoming  the  limitations  and  difficulties  of 
classical drug design efforts.
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